At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
GLP-1 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1
In Brief
A clinical study evaluating GLP-1, Placebo (Saline), and 3 other interventions for Hypoglycaemia. Completed, enrolled 40 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine the role of inflammation and the insulin regulating hormone GLP-1 during critical illness.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoglycaemia
CountriesDenmark
CollaboratorsUniversity of Copenhagen, Novo Nordisk A/S
Timeline
N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2011
First PostedMay 2011
Primary CompletionSep 2014
TodayJul 2026
First PostedMay 4, 2011
Enrollment StartMar 1, 2011
Primary CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 15.2 years ago
Interventions
GLP-1drug
GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
Placebo (Saline)drug
Normal saline (NaCl 0,9%)
TNF-alfadrug
1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
OGTTother
Oral glucose tolerance test with 75 g glucose
IVGTTother
Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT